Phathom Pharmaceuticals (PHAT) Financials: History & Chart

Phathom Pharmaceuticals, Inc.(PHAT)

Biotechnology · Florham Park, NJ

$6.71+0.01 (+0.21%)

Delayed quote: Oct 6, 2026, 3:10 PM EDT

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Florham Park, NJ

371 employees

www.phathompharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steven L. Basta

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	239.66M	74.27M	58.30M	57.58M	49.50M	39.50M	28.52M	29.66M	16.35M
Cost of Goods Sold	40.93M	15.10M	12.00M	7.65M	6.19M	5.04M	3.72M	3.81M	2.36M
Gross Profit	198.73M	59.18M	46.30M	49.94M	43.31M	34.47M	24.80M	25.85M	14.00M
Gross Profit Margin	82.9%	79.7%	79.4%	86.7%	87.5%	87.2%	86.9%	87.1%	85.6%
Total Operating Expenses	239.37M	63.14M	61.78M	55.86M	58.59M	94.39M	103.66M	85.27M	84.79M
Research & Development	30.10M	7.81M	7.77M	7.49M	7.03M	9.08M	9.18M	8.58M	8.69M
Selling, General & Administrative	209.27M	55.33M	54.01M	48.37M	51.56M	85.31M	94.47M	76.68M	76.10M
Operating Income (EBIT)	-40.64M	-3.96M	-15.48M	-5.93M	-15.27M	-59.92M	-78.86M	-59.42M	-70.80M
Operating Margin	-17.0%	-5.3%	-26.5%	-10.3%	-30.8%	-151.7%	-276.5%	-200.3%	-433.0%
Income Before Tax (EBT)	-99.07M	-17.58M	-30.37M	-21.15M	-29.97M	-75.81M	-94.32M	-74.45M	-85.58M
Interest Income	5.86M	1.51M	1.74M	1.20M	1.41M	1.79M	2.64M	3.51M	3.71M
Interest Expense	63.43M	15.10M	15.80M	16.42M	16.11M	17.52M	18.07M	18.59M	18.48M
Other Income/Expense	-58.43M	-13.62M	-14.89M	-15.22M	-14.70M	-15.89M	-15.45M	-15.03M	-14.78M
Net Income	-99.07M	-17.58M	-30.37M	-21.15M	-29.97M	-75.81M	-94.32M	-74.45M	-85.58M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-41.3%	-23.7%	-52.1%	-36.7%	-60.5%	-191.9%	-330.7%	-251.0%	-523.3%
EBITDA	-40.13M	-3.85M	-15.37M	-5.80M	-15.12M	-59.75M	-78.69M	-59.22M	-70.61M
EBITDA Margin	-16.7%	-5.2%	-26.4%	-10.1%	-30.5%	-151.3%	-275.9%	-199.6%	-431.8%
Depreciation & Amortization	508K	114K	110K	128K	156K	172K	177K	193K	191K
EPS Basic	-1.28	-0.21	-0.37	-0.29	-0.41	-1.05	-1.31	-1.05	-1.32
EPS Diluted	-1.28	-0.21	-0.37	-0.29	-0.41	-1.05	-1.31	-1.05	-1.32
Weighted Average Basic Shares	83.75M	83.75M	82.05M	73.82M	73.40M	72.47M	71.97M	71.05M	64.63M
Weighted Average Diluted Shares	83.75M	83.75M	82.05M	73.82M	73.40M	72.47M	71.97M	71.05M	64.63M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	175.11M	55.25M	682K	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold	22.60M	7.97M	167K	620K	521K	300K	8K	0.00
Gross Profit	152.51M	47.28M	515K	-620K	-521K	-300K	-8K	0.00
Gross Profit Margin	87.1%	85.6%	75.5%	N/A	N/A	N/A	N/A	N/A
Total Operating Expenses	312.50M	324.75M	167.83M	171.82M	134.56M	125.36M	106.22M	1.23M
Research & Development	32.78M	34.08M	49.90M	71.44M	72.34M	98.15M	99.27M	20K
Selling, General & Administrative	279.72M	290.66M	117.93M	100.38M	62.22M	27.22M	6.94M	1.21M
Operating Income (EBIT)	-159.99M	-277.47M	-167.31M	-172.44M	-135.08M	-125.67M	-106.22M	-1.23M
Operating Margin	-91.4%	-502.2%	-24532.6%	N/A	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-221.25M	-334.33M	-201.59M	-197.72M	-143.88M	-129.07M	-255.13M	-1.29M
Interest Income	7.04M	15.16M	7.88M	2.13M	41K	1.09M	1.09M	N/A
Interest Expense	68.11M	72.01M	41.97M	27.30M	6.79M	4.58M	4.18M	13K
Other Income/Expense	-61.26M	-56.86M	-34.28M	-25.28M	-8.80M	-3.40M	-148.92M	-63K
Net Income	-221.25M	-334.33M	-201.59M	-197.72M	-143.88M	-129.07M	-209.74M	-1.29M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13K
Net Profit Margin	-126.3%	-605.1%	-29558.9%	N/A	N/A	N/A	N/A	N/A
EBITDA	-159.35M	-276.67M	-166.74M	-171.82M	-134.56M	-125.36M	-106.21M	0.00
EBITDA Margin	-91.0%	-500.7%	-24448.2%	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	633K	795K	575K	620K	521K	300K	8K	1.23M
EPS Basic	-3.03	-5.29	-3.93	-5.70	-4.00	-4.01	-8.48	-0.15
EPS Diluted	-3.03	-5.29	-3.93	-5.70	-4.00	-4.01	-8.48	-0.15
Weighted Average Basic Shares	72.92M	63.18M	51.29M	39.12M	37.00M	33.23M	24.73M	8.58M
Weighted Average Diluted Shares	72.92M	63.18M	51.29M	39.12M	37.00M	33.23M	24.73M	8.58M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.